Your session is about to expire
← Back to Search
Community Health Navigator Program for Chronic Conditions (ENCOMPASS Trial)
N/A
Waitlist Available
Led By Kerry A McBrien, MD, MPH
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Stage 3b or greater chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73m2 in past year)
Established ischemic heart disease (at least one instance of a physician billing diagnosis with a relevant International Classification of Diseases, 9th Edition [ICD-9] code recorded in electronic medical record (EMR), or known to health care team)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 36 months
Awards & highlights
ENCOMPASS Trial Summary
This trial is testing a community health navigator program to see if it can help patients with multiple long-term health conditions get the care and resources they need.
Who is the study for?
This trial is for individuals with multiple long-term health conditions like severe high blood pressure, heart failure, ischemic heart disease, advanced kidney disease (stage 3b or greater), COPD or asthma with frequent visits, and poorly controlled diabetes. Participants must be able to consent and not live in a long-term care facility.Check my eligibility
What is being tested?
The ENCOMPASS study tests a Community Health Navigator Program where trained community members help patients navigate the healthcare system. It aims to improve access to services for those with complex health conditions in Alberta.See study design
What are the potential side effects?
Since this intervention involves guidance rather than medication, typical drug side effects are not expected. However, there may be indirect effects related to changes in healthcare utilization.
ENCOMPASS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidney function is reduced, with a filtration rate below 45 mL/min.
Select...
I have been diagnosed with heart disease.
Select...
I have COPD or asthma and have seen a doctor for it at least twice last year.
Select...
I have been diagnosed with congestive heart failure.
Select...
My diabetes has been poorly controlled, with an A1C over 9% in the past year.
ENCOMPASS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 36 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Acute care service use
Secondary outcome measures
Acute care costs
All-cause mortality
Anxiety symptoms
+21 moreENCOMPASS Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Community health navigator program for six months.
Group II: ControlActive Control1 Intervention
Usual health care.
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
780 Previous Clinical Trials
841,551 Total Patients Enrolled
11 Trials studying Coronary Artery Disease
10,613 Patients Enrolled for Coronary Artery Disease
Kerry A McBrien, MD, MPHPrincipal InvestigatorUniversity of Calgary
3 Previous Clinical Trials
333 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
333 Patients Enrolled for Coronary Artery Disease
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your blood pressure is consistently too high, especially the top number being above 160.My kidney function is reduced, with a filtration rate below 45 mL/min.I am unable to understand and give consent for treatment.I have been diagnosed with heart disease.I have COPD or asthma and have seen a doctor for it at least twice last year.I have been diagnosed with congestive heart failure.You live in a nursing home or assisted living facility.My diabetes has been poorly controlled, with an A1C over 9% in the past year.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants are being selected for this clinical investigation?
"Affirmative, according to clinicaltrials.gov this research is actively looking for volunteers. It was first posted on March 10th 2021 and the last update was November 1st 2022. 400 participants need to be enrolled between a single site."
Answered by AI
Are there any remaining vacancies for this research initiative?
"Correct. Evidence found on clinicaltrials.gov reveals that, since its inception in March 2021, this medical study is actively seeking enrolments from 400 patients across a single site. It was last modified on the 1st of November 2022."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger